Review Articles

Management of Pulmonary Hypertension in Left Heart Disease

Authors:

Abstract

Pulmonary hypertension due to left heart diseases (PH-LHD) is the most prevalent form of pulmonary hypertension. It frequently complicates heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) and negatively impacts prognosis, particularly when a precapillary component is present.

PH-LHD is distinctive from pulmonary arterial hypertension (PAH) even though both conditions may share some common characteristics. In addition, the mechanisms involved in the development of a precapillary component are yet to be fully clarified, in particular in PH due to HFpEF.

Several studies have been exploring PAH pathways as potential therapies for PH-LHD, but no PAH-approved drug has demonstrated efficacy in PH-LHD. Rather, some classes of drugs, such as endothelin-receptor antagonists or prostacycline-analogues, have been found to be harmful in patients with HF. Therefore, at present, the only established treatments for PH-LHD are those that target the heart as recommended in the international guidelines for HF. Based on current knowledge, off-label prescription of PAH-approved drugs in PH-LHD patients must be strongly discouraged.

Keywords:

pulmonary hypertensionheart failurepulmonary circulationleft heart diseasehemodynamics
  • Year: 2021
  • Volume: 17 Issue: 2
  • Page/Article: 115-123
  • DOI: 10.14797/RKQN5397
  • Accepted on 18 Nov 2020
  • Published on 1 Jul 2021
  • Peer Reviewed